Background: Spinal cord injury (SCI) impairs sensory and motor functions, resulting in significant physical, psychological, and financial impacts. In Asia, SCI incidence ranges from 12.06 to 61.6 cases per million, lower than North America's 27.1 to 83.0 cases per million. Glucocorticoids like dexamethasone are used for SCI treatment but have limitations due to high-dose complications. Resveratrol, a polyphenol with antioxidative and anti-inflammatory properties, shows promise in central nervous system protection but requires further investigation for SCI. Methods: This systematic review and meta-analysis follows PRISMA guidelines and is registered with PROSPERO (Code: CRD42024569681). It will assess resveratrol's effects on motor function (BBB/BMS score), anti-inflammatory proteins (IL-10, IL-6, TNF-α, IL-1β), and antioxidants (SOD, MDA, GSh) in SCI rat models. Searches will be conducted in PubMed/MEDLINE, Embase, Scopus, and Web of Science using relevant keywords, synonyms, MeSH, and EMTREE terms, including grey literature. Eligible studies will involve rats with traumatic SCI and resveratrol treatment, excluding combination therapies or different control groups. Two independent reviewers will screen and review studies, with a third reviewer resolving disagreements. Data will be extracted into an Excel sheet, covering study design, animal models, interventions, and outcomes. The SYRCLE tool will assess bias, and the GRADE scale will determine evidence certainty, with discrepancies resolved by discussion or third-party input. Discussion: This review aims to elucidate resveratrol's potential to improve motor function and provide anti-inflammatory and antioxidant effects in SCI, potentially offering a non-toxic, cost-effective treatment option.
Peyrovinasab et al. (Fri,) studied this question.